Nanologica AB (OSTO:NICA) Cash-to-Debt : 12.11 (As of Jun. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Nanologica AB Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Nanologica AB's cash to debt ratio for the quarter that ended in Jun. 2024 was 12.11.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Nanologica AB could pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.

The historical rank and industry rank for Nanologica AB's Cash-to-Debt or its related term are showing as below:

OSTO:NICA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.11 Med: 3.82 Max: 28.16
Current: 12.11

During the past 10 years, Nanologica AB's highest Cash to Debt Ratio was 28.16. The lowest was 0.11. And the median was 3.82.

OSTO:NICA's Cash-to-Debt is ranked better than
58.69% of 1508 companies
in the Biotechnology industry
Industry Median: 6.11 vs OSTO:NICA: 12.11

Nanologica AB Cash-to-Debt Historical Data

The historical data trend for Nanologica AB's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Nanologica AB Cash-to-Debt Chart

Nanologica AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.11

5.24

1.20

14.99

15.10

Nanologica AB Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Cash-to-Debt	Get a 7-Day Free Trial															15.93	18.85	15.10	11.06	12.11

Competitive Comparison of Nanologica AB's Cash-to-Debt

For the Biotechnology subindustry, Nanologica AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nanologica AB's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanologica AB's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Nanologica AB's Cash-to-Debt falls into.

Nanologica AB Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Nanologica AB's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	10.054	/	(0.53	+	0.136)
	=	15.10

Nanologica AB's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	15.076	/	(1.148	+	0.097)
	=	12.11

Nanologica AB (OSTO:NICA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Nanologica AB Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Nanologica AB's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanologica AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanologica AB (OSTO:NICA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Forskargatan 20G, Södertälje, SWE, SE-151 36

Website

https://www.nanologica.com

Nanologica AB develops and manufactures nanoporous silica particles for life science applications. It focuses on two areas: Drug Development and Chromatography. The company's drug delivery platforms are NLAB Spiro and NLAB Silica, which aim to produce better medicines for the benefit of patients. Its geographical segments are Sweden, China, the United States, and the Rest of the world.

Nanologica AB Headlines

No Headlines